Edition:
United Kingdom

Rigel Pharmaceuticals Inc (RIGL.OQ)

RIGL.OQ on NASDAQ Stock Exchange Global Select Market

3.56USD
15 Dec 2017
Change (% chg)

$-0.01 (-0.28%)
Prev Close
$3.57
Open
$3.66
Day's High
$3.68
Day's Low
$3.42
Volume
4,968,851
Avg. Vol
460,970
52-wk High
$4.47
52-wk Low
$1.94

Latest Key Developments (Source: Significant Developments)

Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017
Friday, 15 Dec 2017 

Dec 15 (Reuters) - Rigel Pharmaceuticals Inc ::RIGEL ANNOUNCES DEPARTURE OF CHIEF FINANCIAL OFFICER.RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017.COMPANY HAS INITIATED AN EXTERNAL SEARCH FOR ITS NEXT CHIEF FINANCIAL OFFICER.NELSON CABATUAN, RIGEL'S VICE PRESIDENT, FINANCE WILL SERVE AS COMPANY'S INTERIM PRINCIPAL ACCOUNTING OFFICER.  Full Article

Rigel announces Q3 loss of $0.14 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces third quarter 2017 financial results and provides company update.Q3 loss per share $0.14.  Full Article

Rigel announces pricing of public offering of common stock
Thursday, 5 Oct 2017 

Oct 4 (Reuters) - Rigel Pharmaceuticals Inc :Rigel announces pricing of public offering of common stock.Says public offering of 18.1 million common shares priced at $3.35 per share.  Full Article

Rigel Pharmaceuticals q2 loss per share $0.15
Tuesday, 2 Aug 2016 

Rigel Pharmaceuticals Inc : Q2 loss per share $0.15 . Expects cash, cash equivalents and short-term investments as Of June 30 to be sufficient to fund operations into q3 of 2017 . Rigel pharmaceuticals inc qtrly revenues $13.6 million versus $7.4 million .Q2 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Rigel Pharmaceuticals Inc initiates Phase 2 clinical trial of fostamatinib in autoimmune hemolytic anemia
Thursday, 25 Feb 2016 

Rigel Pharmaceuticals Inc:Initiates Phase 2 clinical trial of fostamatinib in autoimmune hemolytic anemia.Rigel expects to have results of the Stage 1 segment of the trial by year-end 2016.  Full Article

BRIEF-Rigel Announces Resignation Of Ryan Maynard, Executive Vice President And CFO Effective December 31, 2017

* RESIGNATION OF RYAN MAYNARD, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, EFFECTIVE DECEMBER 31, 2017